Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects

Pulmonary Pharmacology and Therapeutics

Volumn 12, Issue 6, 1999, Pages 353-362

  Gumbhir Shah, Kavita ^a   Kellerman, Donald J ^a   Degraw, Sidney ^a   Koch, Patrick ^b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

Asthma; Enantiomers; Indirect response; Inhalation; Model; Modeling; Pharmacodynamics; Pharmacokinetics; Salbutamol

Indexed keywords

GLUCOSE; POTASSIUM; SALBUTAMOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG HALF LIFE; DRUG SAFETY; ENANTIOMER; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; MALE; NEBULIZATION; NEUROTOXICITY; PHARMACODYNAMICS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; VERTIGO; WHEEZING;

EID: 0033380238     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1999.0217     Document Type: Article

References (29)

1. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992. International consensus report on diagnosis and treatment of asthma. Eur Respir J. 5:1992;601-641.
2. Kelly H. W., Murphy S. Beta-adrenergic agonists for acute, severe asthma. Ann Pharmacother. 26:1992;81-91.
3. Brittain R. T., Farmer J. B., Marshall R. J. Some observation on the β -adrenoceptor agonist properties of the isomers of salbutamol. Br J Pharmacol. 48:1973;144-147.
4. Johansson F, Rydberg I, Aberg G, Andersson R. G. G. Effects of albuterol enantiomers on in vitro bronchial reactivity. Clin Rev Allergy Immunol. 14:1996;57-64.
5. 2 -adrenergic receptors. Clin Rev Allergy Immunol. 14:1996;37-45.
6. Yamaguchi H, McCullough J. R. S-Albuterol exacerbates calcium responses to carbachol in airway smooth muscle cells. Clin Rev Allergy Immunol. 14:1996;47-55.
7. Chapman I. D., Buchheit K. H., Manley P, Morley J. Active enantiomers may cause adverse effects in asthma. Trends Pharmacol Sci. 13:1992;231-232.
8. Perrin-Fayolle M, Blum P. S., Morley J, Groschlaude M, Chambe M-T. Differential responses of asthmatic airways to enantiomers of albuterol. Clin Rev Allergy Immunol. 14:1996;139-147.
9. Boulton D. W., Fawcett J. P. Enantioselective disposition of albuterol in humans. Clin Rev Allergy Immunol. 14:1996;115-138.
10. Janson C. Plasma levels and effects of salbutamol after inhaled or iv administration in stable asthma. Eur Respir J. 4:1991;544-550.
11. Newnham D. M., Lipworth B. J. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system («Ventstream»). Thorax. 49:1994;762-770.
12. Boulton D. W., Fawcett J. P. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br J Clin Pharmacol. 41:1996;35-40.
13. Boulton D. W., Fawcett J. P. Pharmacokinetics and pharmacodynamics of single oral doses of albuterol and its enantiomers in humans. Clin Pharmacol Ther. 62:1997;138-144.
14. Gumbhir-Shah K, Kellerman D. J., DeGraw S, Koch P, Jusko W. J. Pharmacokinetic and pharmacodynamic characteristics and safety of inhaled albuterol enantiomers in healthy volunteers. J Clin Pharmacol. 38:1998;1096-1106.
15. Fried K. M., Koch P, Wainer I. W. Determination of the enantiomers of albuterol in human and canine plasma by enantioselective high-performance chromatography on a teicoplanin-based chiral stationary phase. Chirality. 10:1998;484-491.
16. Whyte K. F., Addis G. J., Whitesmith R, Reid J. L. The mechanism of salbutamol-induced hypokalemia. Br J Clin Pharmacol. 23:1987;65-71.
17. Smith A. P., Banks J, Buchanan K, Cheong B, Gunawardena K. A. Mechanisms of abnormal glucose metabolism during treatment of acute severe asthma. Q J Med. 82:1992;71-80.
18. Jusko W. J., Ko H. C. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther. 56:1994;406-419.
19. Chazan R, Droszcz W, Maruchin J. E. Pharmacodynamics of salbutamol in humans. Int J Clin Pharmacol Ther Toxicol. 26:1988;385-387.
20. 2adrenoceptor activity of nebulised racemic salbutamol and its R and S isomers in healthy volunteers. Thorax. 52:1997;849-852.
21. Lipworth B. J. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol. 42:1996;697-705.
22. Vaisman N, Koren G, Goldstein D, Canny G. J., Tan Y. K., Soldin S. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr. 111:1987;914-917.
23. Logsdon T. W., Zhou X, Breen P, Anderson P, Gann L, Hiller C. Determination of albuterol in plasma after aerosol inhalation by gas chromatography-mass spectrometry with selected-ion monitoring. J Chromatogr B. 692:1997;472-477.
24. Lipworth B. J., McDevitt D. G. Beta-adrenoceptor responses to inhaled salbutamol in normal subjects. Eur J Clin Pharmacol. 36:1989;239-245.
25. Bennett J. A., Smyth E. T., Pavord I. D., Wilding P. J., Tattersfield A. E. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax. 49:1994;771-774.
26. Lipworth B. J., Clark R. A., Dhillon D. P., Brown R. A., McDevitt D. G. Extrapulmonary effects of high dose inhaled salbutamol in normal and asthmatic subjects. Eur Respir J. 9 (suppl 2):1988;199S.
27. Lipworth B. J., Struthers A. D., McDevitt D. G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 140:1989;586-592.
28. Dayneka N. L., Garg V, Jusko W. J. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 21:1993;457-478.
29. Sharma A, Jusko W. J. Characterization of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol. 45:1998;229-239.